To reduce our
derivatives-related
credit risk, we regularly seek the execution of master agreements (such as the International
Swaps and Derivatives Association’s master agreements for derivatives) with our clients. A master agreement allows the netting of obligations arising under all of the
derivatives transactions that the agreement covers upon the counterparty’s default, resulting in a single net claim against the counterparty (called “close-out netting”). For parts of our derivatives business we also enter into payment
netting agreements under which we set off amounts payable on the same day in the same currency and in respect to all transactions covered by these agreements, reducing our principal risk.
For internal credit
exposure measurement purposes, we only apply netting when we believe it is legally enforceable for the relevant jurisdiction and counterparty. Also, we enter into collateral support agreements to reduce our derivatives-related credit risk. These collateral arrangements generally provide risk mitigation through periodic (usually daily) margining of the covered
portfolio or transactions and termination of the master agreement if the counterparty fails to honor a collateral call. As with netting, when we believe the collateral agreement is enforceable we reflect this in our exposure measurement.
As the replacement values of our portfolios fluctuate with movements in market rates and with changes in the transactions in the portfolios, we also estimate the potential future replacement costs of the portfolios over their lifetimes or, in case of collateralized portfolios, over appropriate unwind periods. We measure our potential future exposure against separate limits. We supplement our potential future
exposure analysis with stress tests to estimate the immediate impact of extreme market events on our exposures (such as event risk in our
Emerging Markets portfolio).
Treatment of Default Situations under Derivatives
Unlike in the case of our standard loan assets, we generally have more
options to manage the credit risk in our
OTC derivatives when movement in the current replacement costs of the transactions and the behavior of our counterparty indicate that there is the risk that upcoming payment obligations under the transactions might not be honored. In these situations, we are frequently able to obtain additional collateral or terminate the transactions or the related master agreement.
When our decision to terminate transactions or the related master agreement results in a residual net obligation of the counterparty, we restructure the obligation into a nonderivative claim and manage it through our regular workout process. As a consequence, we do not show any nonperforming derivatives.
The following table shows the notional amounts and gross market values of OTC and exchange-traded derivative contracts we held for trading and nontrading purposes as of December 31, 2007.
|
Dec 31, 2007 |
Notional amount maturity distribution |
Positive market value |
Negative market value |
Net market value | |||
|---|---|---|---|---|---|---|---|
|
in € m. |
Within one year |
> 1 and |
After five years |
Total | |||
|
Interest-rate-related transactions: |
|
|
|
|
|
|
|
|
OTC products: |
|
|
|
|
|
|
|
|
FRAs |
2,528,018 |
136,002 |
514 |
2,664,534 |
1,631 |
(1,777) |
(146) |
|
Interest rate swaps |
10,152,957 |
10,751,638 |
8,353,640 |
29,258,235 |
289,573 |
(293,223) |
(3,649) |
|
Purchased interest rate options |
153,287 |
577,440 |
757,539 |
1,488,266 |
34,876 |
– |
34,876 |
|
Written interest rate options |
282,071 |
609,398 |
855,179 |
1,746,647 |
– |
(37,798) |
(37,798) |
|
Other interest rate trades |
– |
– |
– |
– |
– |
– |
– |
|
Exchange-traded products: |
|
|
|
|
|
|
|
|
Interest rate |
415,050 |
99,189 |
867 |
515,106 |
– |
– |
– |
|
Purchased interest rate |
155,816 |
13,494 |
– |
169,310 |
352 |
– |
352 |
|
Written interest rate options |
93,063 |
18,640 |
– |
111,703 |
– |
(300) |
(300) |
|
Sub-total |
13,780,263 |
12,205,800 |
9,967,738 |
35,953,801 |
326,432 |
(333,098) |
(6,666) |
|
Currency-related transactions: |
|
|
|
|
|
|
|
|
OTC products: |
|
|
|
|
|
|
|
|
Forward exchange trades |
607,058 |
47,826 |
4,159 |
659,043 |
9,148 |
(9,077) |
71 |
|
Cross currency swaps |
1,797,862 |
569,054 |
379,216 |
2,746,132 |
47,709 |
(48,683) |
(974) |
|
Purchased foreign |
362,173 |
85,209 |
23,969 |
471,352 |
12,035 |
– |
12,035 |
|
Written foreign currency options |
382,422 |
88,371 |
25,449 |
496,242 |
– |
(11,764) |
(11,764) |
|
Exchange-traded products: |
|
|
|
|
|
|
|
|
Foreign currency futures |
9,652 |
597 |
35 |
10,285 |
– |
– |
– |
|
Purchased foreign currency options |
2,606 |
10 |
– |
2,616 |
13 |
– |
13 |
|
Written foreign currency options |
1,401 |
– |
– |
1,401 |
– |
(36) |
(36) |
|
Sub-total |
3,163,174 |
791,068 |
432,828 |
4,387,071 |
68,905 |
(69,560) |
(655) |
|
Equity/index-related transactions: |
|
|
|
|
|
|
|
|
OTC products: |
|
|
|
|
|
|
|
|
Equity forward |
2,816 |
– |
– |
2,816 |
47 |
(24) |
23 |
|
Equity/index |
95,637 |
37,668 |
8,633 |
141,938 |
6,048 |
(5,685) |
363 |
|
Purchased equity/index options |
147,055 |
93,230 |
23,686 |
263,970 |
39,385 |
– |
39,385 |
|
Written equity/index options |
156,430 |
119,771 |
35,365 |
311,566 |
– |
(47,533) |
(47,533) |
|
Exchange-traded products: |
|
|
|
|
|
|
|
|
Equity/index futures |
42,090 |
– |
– |
42,090 |
– |
– |
– |
|
Equity/index purchased options |
182,829 |
63,994 |
9,778 |
256,601 |
20,393 |
– |
20,393 |
|
Equity/index written options |
172,540 |
64,863 |
11,967 |
249,370 |
– |
(24,194) |
(24,194) |
|
Sub-total |
799,397 |
379,526 |
89,428 |
1,268,351 |
65,873 |
(77,436) |
(11,563) |
|
236,587 |
3,428,971 |
1,492,936 |
5,158,493 |
119,238 |
(106,410) |
12,828 | |
|
Other transactions: |
|
|
|
|
|
|
|
|
OTC products: |
|
|
|
|
|
|
|
|
Precious metal trades |
53,091 |
33,606 |
5,287 |
91,984 |
5,684 |
(4,456) |
1,227 |
|
Other trades |
108,803 |
186,371 |
8,565 |
303,739 |
17,831 |
(18,084) |
(253) |
|
Exchange-traded products: |
|
|
|
|
|
|
|
|
17,723 |
7,028 |
37 |
24,788 |
66 |
(87) |
(22) | |
|
Purchased options |
12,402 |
5,525 |
10 |
17,938 |
1,560 |
– |
1,560 |
|
Written options |
12,113 |
5,289 |
156 |
17,558 |
– |
(1,712) |
(1,712) |
|
Sub-total |
204,132 |
237,819 |
14,055 |
456,006 |
25,140 |
(24,339) |
801 |
|
Total OTC business |
17,066,267 |
16,764,555 |
11,974,136 |
45,804,957 |
583,204 |
(584,514) |
(1,309) |
|
Total exchange-traded business |
1,117,286 |
278,629 |
22,850 |
1,418,765 |
22,384 |
(26,329) |
(3,945) |
|
Total |
18,183,553 |
17,043,184 |
11,996,986 |
47,223,723 |
605,588 |
(610,843) |
(5,255) |
|
Positive market values after netting agreements |
|
|
|
|
120,265 |
|
|

